186 related articles for article (PubMed ID: 36192229)
1. Adjuvant radiation therapy improves survival in stage IIIA (N2) non-small cell lung cancer with persistent N2 disease after neoadjuvant chemotherapy.
Komiya T; Takamori S; Wilding G
Radiother Oncol; 2022 Nov; 176():234-238. PubMed ID: 36192229
[TBL] [Abstract][Full Text] [Related]
2. Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio.
Shinde A; Horne ZD; Li R; Glaser S; Massarelli E; Koczywas M; Erhunmwunsee L; Reckamp KL; Weksler B; Salgia R; Beriwal S; Amini A
Lung Cancer; 2019 Jul; 133():136-143. PubMed ID: 31200820
[TBL] [Abstract][Full Text] [Related]
3. Postoperative radiotherapy with modern techniques does not improve survival for operable stage IIIA-N2 non-small cell lung cancer.
Predina J; Suliman R; Potter AL; Panda N; Diao K; Lanuti M; Muniappan A; Jeffrey Yang CF
J Thorac Cardiovasc Surg; 2023 May; 165(5):1696-1709.e4. PubMed ID: 36610886
[TBL] [Abstract][Full Text] [Related]
4. Is There a Survival Benefit in Patients With Stage IIIA (N2) Non-small Cell Lung Cancer Receiving Neoadjuvant Chemotherapy and/or Radiotherapy Prior to Surgical Resection: A Systematic Review and Meta-analysis.
Xu YP; Li B; Xu XL; Mao WM
Medicine (Baltimore); 2015 Jun; 94(23):e879. PubMed ID: 26061306
[TBL] [Abstract][Full Text] [Related]
5. Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non-small cell lung cancer: A propensity-matched analysis.
Brandt WS; Yan W; Zhou J; Tan KS; Montecalvo J; Park BJ; Adusumilli PS; Huang J; Bott MJ; Rusch VW; Molena D; Travis WD; Kris MG; Chaft JE; Jones DR
J Thorac Cardiovasc Surg; 2019 Feb; 157(2):743-753.e3. PubMed ID: 30415902
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors in neoadjuvant treatment followed by surgery in stage IIIA-N2 non-small cell lung cancer: a multi-institutional study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).
Couñago F; Montemuiño S; Martin M; Taboada B; Calvo-Crespo P; Samper-Ots MP; Alcántara P; Corona J; López-Guerra JL; Murcia-Mejía M; López-Mata M; Jové-Teixidó J; Chust M; Díaz-Díaz V; de Ingunza-Barón L; García-Cañibano T; Couselo ML; Del Cerro E; Moradiellos J; Amor S; Varela A; Puertas MM; Thuissard IJ; Sanz-Rosa D; de Dios NR
Clin Transl Oncol; 2019 Jun; 21(6):735-744. PubMed ID: 30430394
[TBL] [Abstract][Full Text] [Related]
7. Adding Radiotherapy to Adjuvant Chemotherapy Does Not Improve Survival of Patients With N2 Lung Cancer.
Drake JA; Portnoy DC; Tauer K; Weksler B
Ann Thorac Surg; 2018 Oct; 106(4):959-965. PubMed ID: 29856974
[TBL] [Abstract][Full Text] [Related]
8. Management of stage IIIA non-small cell lung cancer by thoracic surgeons in North America.
Veeramachaneni NK; Feins RH; Stephenson BJ; Edwards LJ; Fernandez FG
Ann Thorac Surg; 2012 Sep; 94(3):922-6; discussion 926-8. PubMed ID: 22742842
[TBL] [Abstract][Full Text] [Related]
9. The impact of order with radiation therapy in stage IIIA pathologic N2 NSCLC patients: a population-based study.
Duan H; Liang L; Xie S; Wang C
BMC Cancer; 2020 Aug; 20(1):809. PubMed ID: 32847544
[TBL] [Abstract][Full Text] [Related]
10. Persistent N2 disease after neoadjuvant chemotherapy for non-small-cell lung cancer.
Higgins KA; Chino JP; Ready N; Onaitis MW; Berry MF; D'Amico TA; Kelsey CR
J Thorac Cardiovasc Surg; 2011 Nov; 142(5):1175-9. PubMed ID: 22014344
[TBL] [Abstract][Full Text] [Related]
11. The Prognostic Role of PORT and EGFR Mutation Status in Completely Resected Stage IIIA/N2 Non-Small Cell Lung Cancer Patients with Postoperative Chemotherapy.
Yang H; Wang K; Li S; Li Y; Yuan L
Pathol Oncol Res; 2021; 27():1609898. PubMed ID: 34447289
[No Abstract] [Full Text] [Related]
12. Analysis of Patients Unable to Undergo Adjuvant Chemotherapy after Surgery in Stage IIIA/B Non-Small Cell Lung Cancer: Will They Benefit from Mediastinal Radiotherapy?
Graeter TP; Sebastian B; Bischof M; Kugler G; Fischer JR; Schneider T
Thorac Cardiovasc Surg; 2016 Sep; 64(6):501-6. PubMed ID: 26322832
[TBL] [Abstract][Full Text] [Related]
13. Postoperative radiotherapy is effective in improving survival of patients with stage pIII-N2 non-small-cell lung Cancer after pneumonectomy.
Wang W; Men Y; Wang J; Zhou Z; Chen D; Xiao Z; Feng Q; Lv J; Liang J; Bi N; Gao S; Wang L; Hui Z
BMC Cancer; 2019 May; 19(1):478. PubMed ID: 31113432
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of concurrent carboplatin and paclitaxel and thoracic radiotherapy for completely resected stage II and IIIA non-small cell lung cancer.
Feigenberg SJ; Hanlon AL; Langer C; Goldberg M; Nicolaou N; Millenson M; Coia LR; Lanciano R; Movsas B
J Thorac Oncol; 2007 Apr; 2(4):287-92. PubMed ID: 17409799
[TBL] [Abstract][Full Text] [Related]
15. The Significance of Upfront Knowledge of N2 Disease in Non-small Cell Lung Cancer.
Thomas DC; Arnold BN; Rosen JE; Salazar MC; Detterbeck FC; Blasberg JD; Boffa DJ; Kim AW
World J Surg; 2018 Jan; 42(1):161-171. PubMed ID: 28799084
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant treatment followed by surgery versus definitive chemoradiation in stage IIIA-N2 non-small-cell lung cancer: A multi-institutional study by the oncologic group for the study of lung cancer (Spanish Radiation Oncology Society).
Couñago F; Rodriguez de Dios N; Montemuiño S; Jové-Teixidó J; Martin M; Calvo-Crespo P; López-Mata M; Samper-Ots MP; López-Guerra JL; García-Cañibano T; Díaz-Díaz V; de Ingunza-Barón L; Murcia-Mejía M; Alcántara P; Corona J; Puertas MM; Chust M; Couselo ML; Del Cerro E; Moradiellos J; Amor S; Varela A; Thuissard IJ; Sanz-Rosa D; Taboada B
Lung Cancer; 2018 Apr; 118():119-127. PubMed ID: 29571989
[TBL] [Abstract][Full Text] [Related]
17. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
Zhong WZ; Wang Q; Mao WM; Xu ST; Wu L; Shen Y; Liu YY; Chen C; Cheng Y; Xu L; Wang J; Fei K; Li XF; Li J; Huang C; Liu ZD; Xu S; Chen KN; Xu SD; Liu LX; Yu P; Wang BH; Ma HT; Yan HH; Yang XN; Zhou Q; Wu YL;
Lancet Oncol; 2018 Jan; 19(1):139-148. PubMed ID: 29174310
[TBL] [Abstract][Full Text] [Related]
18. The role of consolidation therapy for stage III non-small cell lung cancer with persistent N2 disease after induction chemotherapy.
Amini A; Correa AM; Komaki R; Chang JY; Tsao AS; Roth JA; Swisher SG; Rice DC; Vaporciyan AA; Lin SH
Ann Thorac Surg; 2012 Sep; 94(3):914-20. PubMed ID: 22819472
[TBL] [Abstract][Full Text] [Related]
19. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival.
Bueno R; Richards WG; Swanson SJ; Jaklitsch MT; Lukanich JM; Mentzer SJ; Sugarbaker DJ
Ann Thorac Surg; 2000 Dec; 70(6):1826-31. PubMed ID: 11156079
[TBL] [Abstract][Full Text] [Related]
20. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial.
Pless M; Stupp R; Ris HB; Stahel RA; Weder W; Thierstein S; Gerard MA; Xyrafas A; Früh M; Cathomas R; Zippelius A; Roth A; Bijelovic M; Ochsenbein A; Meier UR; Mamot C; Rauch D; Gautschi O; Betticher DC; Mirimanoff RO; Peters S;
Lancet; 2015 Sep; 386(9998):1049-56. PubMed ID: 26275735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
